Studied human medicine at the Albert Ludwig University in Freiburg im Breisgau and at the University of Leeds, UK. Experimental doctorate at the Institute of Physiology at the Freiburg Medical Faculty ("Kidney and colon electrolyte transport in CHIF knockout mice") under Prof. R. Greger and Prof. M. Bleich.
Started specialist training at the University Children's Hospital in Freiburg. After 6 months of further training in pediatric hepatology at the Liver Unit of Birmingham Children's Hospital, UK, transferred to the MHH in June 2008. Specialist examination in December 2009, further training in nutritional medicine in 2012, examination to become a pediatric gastroenterologist in 7/2015.
Dr. Goldschmidt's clinical focus is on pediatric gastroenterology, hepatology and transplant medicine. Her scientific focus is on clinically oriented research projects in the area of ​​liver transplantation, including cognitive function after transplantation in childhood. In 2011, she received the Alex Mowat Prize from ESPGHAN (European Society for Paediatric Gastroenterology, Hepatology and Nutrition) for her work on non-invasive diagnostics of liver fibrosis in children using transient elastography. Dr. Goldschmidt is in charge of the international long-term ChilSFree study on immune monitoring after liver transplantation. Together with Prof. Melk, she is working on cardiovascular risk factors after transplantation. Dr. Goldschmidt is leading the project, relaunched in 2019, to develop and test a training program for children and young people after liver transplantation. In 2018, she was awarded a habilitation scholarship for female scientists at the Hannover Medical School as part of the Ellen Schmidt Program.
Dr. Goldschmidt works as a reviewer for various specialist journals, including the "Journal of Pediatric Gastroenterology and Nutrition" (JPGN) and the annual meetings of ESPGHAN (European Society for Pediatric Gastroenterology, Nutrition and Hepatology). As an investigator, she is in charge of the Reduce Risk Trial at the MHH to optimize therapy in children with Crohn's disease.